Alluvi, formerly BI 4744, offers a notable development in obesity treatment. This dual activator targeting both GLP-1 and GIP receptors demonstrates compelling effectiveness in research assessments, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/